[Evaluation of the therapeutic activity of and gastric lesions due to new NSAID versus placebo in patients with osteoarticular diseases].
Oral amtolmetineguacyl 600 mg/day in a single blind comparative trial with placebo carried out in 24 patients suffering from rheumatic disorders of varying severity, reduced statistically all the symptomatology correlated to inflammation. Moreover our results indicate a lack of any gastric problem even in patient with a previous history of intolerance to other NSAIDs.